4basebio to provide synthetic DNA to tier-one pharma firm
10th Apr 2024 11:55
(Sharecast News) - 4basebio confirmed the provision of its synthetic DNA to an unnamed tier-one pharmaceutical company on Wednesday.
Read more4basebio client gets approval to start trial in Australia
21st Mar 2024 16:11
(Sharecast News) - Synthetic DNA product developer 4basebio announced on Thursday that its client, Helix Nanotechnologies, has achieved a significant milestone with the receipt of HREC approval in Australia.
Read more4basebio inks significant DNA supply contract
1st Mar 2024 13:42
(Sharecast News) - 4basebio announced a significant contract through a competitive tender process on Friday, to provide research and GMP-grade synthetic DNA for the advancement of RNA therapeutics and vaccines at CPI's RNA Centre of Excellence.
Read moreFirst-half losses narrow for 4basebio
21st Sep 2023 13:56
(Sharecast News) - Biotechnology company 4basebio reported revenues from its DNA and Hermes products surpassing £0.2m in its first half on Thursday.
Read more4basebio inks supply deal with Italy's Neomatrix
25th May 2023 15:40
(Sharecast News) - Synthetic DNA biotechnology specialist 4basebio announced a product supply agreement with Neomatrix on Thursday, which it described as an Italian biotech focussed on personalised cancer immunotherapies.
Read more4basebio enters neurofibromatosis collaboration with two universities
10th Jun 2022 12:17
(Sharecast News) - Life sciences company 4basebio announced a collaboration with the University of Alabama (UA) and Teesside University (TU) on Friday, in a research project aimed at developing an effective treatment for neurofibromatosis type-1 (NF1).
Read moreLosses to continue as 4basebio focuses on commercialisation
9th May 2022 11:34
(Sharecast News) - Specialist DNA-focussed life sciences company 4basebio reported revenue of £0.34m in its final results on Monday, down from £0.46m year-on-year.
Read more4basebio inks development deal with Heqet Therapeutics
27th Apr 2022 12:34
(Sharecast News) - Life sciences company 4basebio announced a joint development agreement with Heqet Therapeutics on Wednesday.
Read more4basebio launches two new synthetic DNA products
23rd Mar 2022 15:23
(Sharecast News) - Cell and gene therapy developer 4basebio announced the expansion of its synthetic DNA product offering on Wednesday.
Read more4basebio makes progress with manufacturing development
15th Feb 2022 12:54
(Sharecast News) - Specialist life sciences company 4basebio updated the market on its synthetic DNA business on Tuesday, having added Mark Cooper its as head of manufacturing in December, alongside further senior hires across its manufacturing, quality assurance and business development teams in recent months.
Read more4basebio enters research collaboration with eTheRNA
18th Jan 2022 14:41
(Sharecast News) - Cell and gene therapy intellectual property company 4basebio announced a strategic research collaboration between its wholly-owned subsidiary 4basebio Discovery and eTheRNA immunotherapies on Tuesday.
Read more4basebio enters development deal with T-cell therapy firm Leucid
23rd Nov 2021 13:57
(Sharecast News) - Life sciences company 4basebio announced a joint development agreement between its wholly owned-subsidiary 4basebio Discovery and Leucid Bio on Tuesday, which it said was pioneering "next-generation" chimeric antigen receptor T-cell (CAR-T) therapies for hard-to-treat cancers.
Read more4basebio files for patent on novel DNA type
22nd Jun 2021 08:52
(Sharecast News) - Specialist gene therapy life sciences company 4basebio UK has filed a patent application for a novel protected and stabilised linear synthetic DNA type, dubbed 'osDNA', it announced on Tuesday.
Read more